耳部皮穿式电神经场刺激对患有易怒肠综合征的青少年肠道微生物群的影响:试点研究
Geetanjali Bora1, Samantha N Atkinson2,3, Amy Pan3,4
1Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Journal of digestive diseases
|July 14, 2023
概括
皮肤电神经场刺激 (PENFS) 在青少年中改善了易怒肠综合征 (IBS) 症状. 虽然整体肠道微生物群的多样性没有变化,但优秀的响应者显示蓝菌丰富度增加,这表明特定肠道细菌与治疗成功之间存在潜在联系.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究的研究.
- 神经调节是一种神经调节.
背景情况:
- 刺激性肠综合征 (IBS) 是一种常见的胃肠疾病.
- 大脑-肠-微生物群轴在IBS病理生理学中发挥着作用.
- 阴道神经刺激可能会影响肠道功能和微生物组成.
研究的目的:
- 研究皮肤电神经场刺激 (PENFS) 对青少年IBS患者肠道微生物群的影响.
- 探索PENFS疗效与肠道微生物多样性和丰度的变化之间的潜在相关性.
主要方法:
- 一项前性研究涉及20名女性青少年 (年龄11-18岁) 患有IBS,接受了4周的PENFS.
- 在干预前和后收集便样本进行16S rRNA基因测序.
- 临床结果使用验证的问卷进行评估 (IBS-SSS,VSI,FDI,SRS).
- 微生物组分析包括α和β多样性和差异丰度测试.
主要成果:
- PENFS显著改善了IBS症状,如IBS-SSS,VSI和FDI得分的降低所示 (P < 0.0001).
- 在PENFS前和后的整体肠道微生物群多样性 (α或β) 中没有显著变化.
- 具有优异治疗反应 (≥50点IBS-SSS减少) 的患者在第4周表现出较高的α多样性,相比于没有反应的患者 (P = 0.033).
- 与非响应者相比,优秀的响应者表现出更高的Blautia属的相对丰度.
结论:
- PENFS是一种有效的治疗方法,可以改善青少年IBS患者的症状.
- 接受PENFS治疗并没有对整体肠道微生物群多样性产生实质性变化.
- 在优秀反应者中布劳蒂亚的丰富表明,特定的肠道微生物特征可能预测IBS中PENFS的良好反应.
更多相关视频
相关概念视频
Irritable Bowel Syndrome I: Introduction
322
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
322
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
195
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
195
Irritable Bowel Syndrome III: Medical and Nursing Management
244
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
244
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
357
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
357
Drugs for Treatment of Diarrhea-Predominant IBS
217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217
Drugs for Treatment of Constipation-Predominant IBS
219
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
219


